Streetbeat News

AKESF

Akeso Inc

http://www.akesobio.com/

CEO

Yu Xia

Industry

Research and Development in Biotechnology

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Akeso Inc. will host a conference call on March 31, 2025, to discuss its full-year 2024 financial results and provide updates on its innovative drug development pipeline. The call will feature key management executives, including CEO Dr. Michelle Xia, and will focus on the company's progress in developing bispecific antibodies and other therapeutic candidates across multiple disease areas.

Portfolio Pulse from

March 28, 2025 | 4:45 pm

Akeso Inc. presented promising phase III results for cadonilimab, a PD-1/CTLA-4 bispecific antibody, in treating locally advanced cervical cancer. The COMPASSION-18 study demonstrated a 100% overall response rate, with 84.8% complete response and a 74.9% 12-month progression-free survival rate. The treatment showed a favorable safety profile with no treatment-related deaths.

Portfolio Pulse from

March 21, 2025 | 3:30 am

Portfolio Pulse from

March 21, 2025 | 3:30 am

Akeso Inc.'s anti-PD-1 monoclonal antibody, penpulimab, has received approval from China's NMPA for first-line treatment of nasopharyngeal cancer, expanding its use from third-line treatment.

Portfolio Pulse from

March 17, 2025 | 4:00 am

Akeso, Inc. has published Phase III clinical trial results for its drug ivonescimab, showing its effectiveness as a monotherapy compared to pembrolizumab for treating certain lung cancers. The results were published in The Lancet, highlighting the drug's potential.

Portfolio Pulse from

March 07, 2025 | 5:30 am

Akeso, Inc. has enrolled the first patient in a Phase III clinical trial for ivonescimab, a PD-1/VEGF bispecific antibody, combined with chemotherapy for treating triple-negative breast cancer.

Portfolio Pulse from

February 21, 2025 | 1:00 am

Akeso, Inc. has received IND acceptance from China's NMPA for AK139, a bispecific antibody targeting IL-4Rα and ST2, aimed at treating respiratory and skin diseases.

Portfolio Pulse from

February 14, 2025 | 1:30 am

Akeso, Inc. has enrolled the first patient in a Phase 3 trial for its bispecific antibody, cadonilimab, aimed at treating NSCLC post-chemoradiotherapy.

Portfolio Pulse from

February 13, 2025 | 1:45 am

Akeso, Inc. has completed patient enrollment for its Phase III clinical trial comparing ivonescimab and tislelizumab for first-line treatment of sq-NSCLC. The trial is significant for Akeso's development of its PD-1/VEGF bispecific antibody.

Portfolio Pulse from

February 06, 2025 | 1:45 am

Akeso, Inc. announced that its New Drug Application for gumokimab, a monoclonal antibody targeting IL-17 for treating moderate to severe psoriasis, has been accepted by China's NMPA. This enhances Akeso's product synergy in autoimmune diseases.

Portfolio Pulse from

January 27, 2025 | 2:00 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.